Melanoma progression

Argenziano, G., Fabbrocini, G., Carli, P, DeGiorgi, V. and Delfino, M. (1997) Epilu-minescence microscopy criteria of cutaneous melanoma progression. J Am Acad Dermatol 37, 68-74. 

Felicetti F, Errico MC, Bottero L, Segnahni P, Stoppacciaro A, Biffoni M, Felh N, Mania G, Petrini M, Colombo MP, Peschle C, Care A (2(X)8) The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68 2745-2754... 

Hart, I. R., Birch, M. and Marshall, J. F. (1991). Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev. 70,115-128. 

Lu, C. and Kerbel, R. S. (1993). Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol. 120, 1281-1288. 

Five papers have been published on the value of the L-DOPA/L-tyrosine ratio as a marker of melanoma progression the main biological and clinical results are summarized in Table 4.3. 

K. Stoitchkov, S. Letelber, J.-P. Gamier, B. Bousquet, N. Tsankov, P. Morel, et al.. Melanoma progression and semm L-Dopa/L-tyrosine ratio a comparison with SIOOB, Melanoma Res., 12, 255-262 (2002). 

Reed JA, Finnerty B, Albino AP. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression. Am J Pathol. 1999 155 549-555. 

Pochec E, Litynska A, Amoresano A, Casbarra A (2003) Glycosylation profile of integrin alpha 3 beta 1 changes with melanoma progression. Biochim Biophys Acta 1643 113-123... 

Vuillermoz B, Khoruzhenko A, D Onofrio ME, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart EX, Wegrowski Y. The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 2004 296 294-306. 

Tumor progressiorr. Markov modeling of melanoma progression (Wanek et al., 1994)... 

Wanek, L.A., Elashoff, RM., Goradia, T.M., Morton, D.L., and Cochran, A.J., 1994, Application of multistage Markov modeling to malignant melanoma progression. Cancer, 73, 336-343. 

Stackpole CW, Groszek L, Kalbag SS. Benign-tomalignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J Natl Cancer Inst 1994 86 361-367. 

Shirley SH, Greene VR, Duncan LM, Cabala CA, Grimm EA, Kusewitt DF. Slug expression during melanoma progression. Am J Pathol. 2012 180 2479-89. 

Pierrat MJ, Marsaud V, Mauviel A, Javelaud D. Expression of microphthalmia-associated transcription factor (MITF), which is critical for melanoma progression, is inhibited by both transcription factor GL12 and transforming growth factor-p. J Biol Chem. 2012 287 17996-8004. 

Hao L, Ha JR, Kuzel P, Garcia E, Persad S. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and SnaiL... 

---